Ruboxistaurin


Ruboxistaurin
Ruboxistaurin
Systematic (IUPAC) name
(9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 169939-94-0 YesY
ATC code None
PubChem CID 153999
ChemSpider 135727 YesY
UNII 721809WQCP N
ChEMBL CHEMBL91829 YesY
Chemical data
Formula C28H28N4O3 
Mol. mass 468.546 g/mol
 N(what is this?)  (verify)

Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic peripheral retinopathy. It is currently being investigated by Eli Lilly and Company.

On February, 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the United States Food and Drug Administration for ruboxistaurin,[1] with a request for an additional clinical trial, which would take 5 years to complete.[2]

Mechanism of action

Ruboxistaurin is an inhibitor of protein kinase C-beta.[3]

References

External links